Aprea Therapeutics Stock Rises After Company Reports Second Unconfirmed Case Of Tumor Reduction In Trial The company reported a second unconfirmed partial response in a patient with advanced endometrial cancer being treated at the 220 mg dose level.
APRE Stock Earnings: Aprea Therapeutics Beats EPS, Beats Revenue for Q2 2024 APRE stock results show that Aprea Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
APRE Stock Earnings: Aprea Therapeutics Beats EPS for Q1 2024 APRE stock results show that Aprea Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.
APRE Stock Earnings: Aprea Therapeutics Misses EPS, Misses Revenue for Q4 2023 APRE stock results show that Aprea Therapeutics missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.
Why Is Precision Oncology-Focused Aprea Therapeutics Stock Trading Higher On Monday? FDA clearance for Aprea Therapeutics' APR-1051 IND application, a promising WEE1 kinase inhibitor. Phase 1 trial initiation in 2024, focusing on Cyclin E cancers. $34 million private placement to fund clinical development and ensure company sustainability until 2026.
